This HTML5 document contains 141 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q50526914
rdf:type
wikibase:Item
schema:description
scienca artikolo 2011年學術文章 vitskapeleg artikkel artykuł naukowy scientific article published in September 2011 научная статья videnskabelig artikel wetenschappelijk artikel articol științific artigo científico teaduslik artikkel บทความทางวิทยาศาสตร์ artículo científico publicado en 2011 article scientific artikel ilmiah vetenskaplig artikel სამეცნიერო სტატია artikulong pang-agham vědecký článek artículu científicu vitenskapelig artikkel 2011年学术文章 vedecký článok مقالة علمية نشرت في سبتمبر 2011 2011年学术文章 article scientifique мақолаи илмӣ bilimsel makale 2011年学术文章 scientific article published in September 2011 2011年學術文章 επιστημονικό άρθρο 2011년 논문 artigo científico 2011年學術文章 наукова стаття, опублікована у вересні 2011 2011 nî lūn-bûn bài báo khoa học научна статия 2011年學術文章 articolo scientifico 2011年学术文章 2011年學術文章 tudományos cikk научни чланак সেপ্টেম্বর ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2011年学术文章 artigo científico scientific article published in September 2011 научни чланак מאמר מדעי 2011年学术文章 artikull shkencor wissenschaftlicher Artikel tieteellinen artikkeli naučni članak article científic 2011年の論文
p:P577
wds:Q50526914-9FC353F8-3C22-42AA-8E67-57FB205A0E32
wdt:P577
2011-09-01T00:00:00Z
p:P407
wds:Q50526914-ACD05487-AF0E-4572-AC58-AD2C783319BE
wdt:P407
wd:Q1860
p:P2860
wds:Q50526914-954809F7-4F59-4CC1-9828-94FBF35652E4 wds:Q50526914-2645EAFB-5538-4712-91FF-C1E8DC27D542 wds:Q50526914-3F61E613-90B0-4FF0-87F6-045F85773A73 wds:Q50526914-479E8518-50D4-4D63-942F-3D7860B0088A wds:Q50526914-56B4289F-593A-4425-A44A-AA27808581CA wds:Q50526914-5E168A09-F61D-42AE-BEFB-FD6CDAE47C95 wds:Q50526914-0961D91B-7A88-494A-8F7E-3E7B505BF1DF wds:Q50526914-1A935C03-956F-4859-BCB5-C52C2410B573 wds:Q50526914-A1CD4E60-0DD4-48FB-9FEA-44D7A9FB9A72 wds:Q50526914-C2BBB81D-76F7-4A2F-883C-4D0DC47B2616 wds:Q50526914-6F70A8C9-A51C-4165-9F4B-D072BD73D952
wdt:P2860
wd:Q37186801 wd:Q33376783 wd:Q34123770 wd:Q35044582 wd:Q37222119 wd:Q40391293 wd:Q36964099 wd:Q37722921 wd:Q58865927 wd:Q40648327 wd:Q34304230
p:P2093
wds:Q50526914-F91B90B6-35AC-4A67-8F71-3FED847A1094 wds:Q50526914-F1499487-1B9B-4804-9D02-95B2D5E952B9 wds:Q50526914-F630C4C7-C1E2-4A99-88C7-B989BD121004 wds:Q50526914-E206ADC4-5F73-40C2-BED5-57AD44ED18B5 wds:Q50526914-E0CB37E3-AC41-4324-A0B8-EC36345326CA wds:Q50526914-3ADF3FC2-4ED8-4C4B-A700-152CC0EDA9A6 wds:Q50526914-BEF88487-7129-4FFA-8BCD-F7C90E6FA569 wds:Q50526914-2FFA7D46-32B9-4120-9E5E-CD1969B00533 wds:Q50526914-17F9358C-9E9F-4CAF-9EFE-348EEAD7F3E5 wds:Q50526914-A0B2FEF6-1141-473C-83B0-452FFF3BEEBD wds:Q50526914-9117F7CD-ED16-437F-AF8A-11B351C543AC wds:Q50526914-8AAA7196-0CB1-40CE-A8F6-15A2BB0839D7 wds:Q50526914-8C2664E4-F5D5-4C43-97F6-267439C2C167 wds:Q50526914-7F669B9C-51FF-4C99-BE87-35695BF2CC18
wdt:P2093
Deborah Mulford Gail L Brown Mikkael Sekeres Daruka Mahadevan Rami S Komrokji Ralph V Boccia Azra Raza John Godwin Dale Schaar Naomi Galili Scott E Smith Han Myint Alan F List Mark Rarick
rdfs:label
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
skos:prefLabel
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
schema:name
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
p:P50
wds:Q50526914-A78E2442-3BF4-4795-8549-15EF28AC2CBA
wdt:P50
wd:Q64026412
p:P1476
wds:Q50526914-13EBC971-FBF6-4E17-9088-D3BBF11A1605
wdt:P1476
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
p:P304
wds:Q50526914-E91138C3-17A0-4820-99A7-1E7E7356CCA6
wdt:P304
2138-2147
p:P31
wds:Q50526914-4018C447-2031-4AF7-A3D1-271FC6CE15C8
wdt:P31
wd:Q13442814
p:P698
wds:Q50526914-CD68E10A-2B10-4F10-9800-75E6CC2A5F71
wdtn:P698
n11:21887679
wdt:P698
21887679
p:P1433
wds:Q50526914-8E305FA9-BB2F-43E3-BD1C-E3985C90CD33
wdt:P1433
wd:Q326041
p:P433
wds:Q50526914-01E97D3E-E46E-429F-A56A-FB042EBC7A6C
p:P478
wds:Q50526914-14276D2B-0F27-4571-B73A-954F5AC7143B
wdt:P433
8
wdt:P478
118
p:P356
wds:Q50526914-A542A9B0-8E69-481A-8C59-EE074E43F19C
wdtn:P356
n10:CNCR.26469
wdt:P356
10.1002/CNCR.26469
p:P5875
wds:Q50526914-CD6DAD74-7FD6-410C-A521-23C78F53D651
wdt:P5875
51615224